Research analysts at Roth Capital assumed coverage on shares of Syros Pharmaceuticals, Inc. (NASDAQ:SYRS) in a report released on Monday, Marketbeat.com reports. The brokerage set a “neutral” rating and a $15.00 price target on the stock. Roth Capital’s price objective would indicate a potential downside of 12.08% from the stock’s current price.

Several other brokerages have also weighed in on SYRS. JMP Securities upgraded shares of Syros Pharmaceuticals from a “market perform” rating to an “outperform” rating and set a $33.00 target price on the stock in a research report on Thursday, September 28th. ValuEngine upgraded shares of Syros Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Monday, July 17th. Cann restated a “buy” rating and set a $28.00 target price on shares of Syros Pharmaceuticals in a research report on Monday, August 21st. Zacks Investment Research upgraded shares of Syros Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Tuesday, October 17th. Finally, Cowen and Company restated a “buy” rating on shares of Syros Pharmaceuticals in a research report on Wednesday, August 9th. One analyst has rated the stock with a sell rating, two have given a hold rating and six have assigned a buy rating to the stock. The stock has an average rating of “Buy” and a consensus target price of $24.47.

Syros Pharmaceuticals (NASDAQ SYRS) traded up 3.33% during midday trading on Monday, hitting $17.06. The stock had a trading volume of 153,236 shares. Syros Pharmaceuticals has a 12 month low of $10.22 and a 12 month high of $24.38. The stock’s market cap is $448.00 million. The stock has a 50 day moving average of $16.10 and a 200 day moving average of $16.10.

Syros Pharmaceuticals (NASDAQ:SYRS) last issued its quarterly earnings results on Wednesday, August 9th. The company reported ($0.52) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.55) by $0.03. Analysts expect that Syros Pharmaceuticals will post ($2.09) EPS for the current fiscal year.

TRADEMARK VIOLATION WARNING: “Syros Pharmaceuticals, Inc. (SYRS) Now Covered by Roth Capital” was reported by American Banking News and is the sole property of of American Banking News. If you are viewing this report on another site, it was illegally copied and republished in violation of US and international copyright and trademark legislation. The correct version of this report can be viewed at https://www.americanbankingnews.com/2017/10/23/syros-pharmaceuticals-inc-syrs-now-covered-by-roth-capital.html.

In other Syros Pharmaceuticals news, insider Eric R. Olson sold 12,500 shares of the company’s stock in a transaction dated Tuesday, July 25th. The shares were sold at an average price of $21.85, for a total value of $273,125.00. Following the sale, the insider now owns 12,500 shares of the company’s stock, valued at $273,125. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Richard A. Young sold 3,282 shares of the company’s stock in a transaction dated Tuesday, July 25th. The shares were sold at an average price of $22.09, for a total transaction of $72,499.38. Following the completion of the sale, the director now directly owns 423,383 shares in the company, valued at approximately $9,352,530.47. The disclosure for this sale can be found here. Insiders have sold 22,114 shares of company stock worth $485,636 over the last 90 days. 33.60% of the stock is currently owned by company insiders.

Hedge funds and other institutional investors have recently made changes to their positions in the business. ARK Investment Management LLC lifted its holdings in shares of Syros Pharmaceuticals by 114.7% in the second quarter. ARK Investment Management LLC now owns 17,705 shares of the company’s stock valued at $285,000 after purchasing an additional 9,460 shares in the last quarter. Redmile Group LLC lifted its holdings in shares of Syros Pharmaceuticals by 2.2% in the second quarter. Redmile Group LLC now owns 973,260 shares of the company’s stock valued at $15,660,000 after purchasing an additional 20,520 shares in the last quarter. Wells Fargo & Company MN purchased a new stake in shares of Syros Pharmaceuticals in the first quarter valued at about $225,000. FMR LLC lifted its holdings in shares of Syros Pharmaceuticals by 11.9% in the second quarter. FMR LLC now owns 3,926,998 shares of the company’s stock valued at $63,185,000 after purchasing an additional 418,061 shares in the last quarter. Finally, Bank of New York Mellon Corp purchased a new stake in shares of Syros Pharmaceuticals in the first quarter valued at about $185,000. 59.61% of the stock is currently owned by institutional investors.

About Syros Pharmaceuticals

Syros Pharmaceuticals, Inc is a biopharmaceutical company. The Company offers a gene control platform designed to analyze the unexploited region of deoxyribonucleic acid (DNA) in human disease tissue to identify and drug targets linked to genomically defined patient populations. The Company is focused on developing treatments for cancer and immune-mediated diseases and is building a pipeline of gene control medicines.

Analyst Recommendations for Syros Pharmaceuticals (NASDAQ:SYRS)

Receive News & Ratings for Syros Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Syros Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.